why are we here?

contents

a.    Pitch Deck:   product, buisiness model, vision, team.

b.    Intellectual Asset Portfolio: what is unique about the product?

c.    Market: size, growth, beachhead, dynamics, competition.

d.    Monetization: B2C and B2B offers.

e.    Operation: costs, legal compliance, headcounts.

f.     Appendix: appendix

The product is a better way to find biomarkers for researchers

pitch deck

pitch deck

• cost of drug discovery has skyrocketed.
• despite advances in high-throughput biotechnology (cloning, sequencing)
• high-throughput still requires manual work by highly qualified personnel.
  Especially the part of data analysis and bioinformatics.

parts of the R&D process has improved yet overall efficiency has declined

Eroom's law

Shannell et al. (2012) Nature. Rev. Drug Discovery

pitch deck

• cost of drug discovery has skyrocketed.
• despite advances in high-throughput biotechnology (cloning, sequencing)
• high-throughput still requires manual work by highly qualified personnel.
  Especially the part of data analysis and bioinformatics.

parts of the R&D process has improved yet overall efficiency has declined

Eroom's law

Shannell et al. (2012) Nature. Rev. Drug Discovery

pitch deck

sequencing costs have plummeted

genome.gov/sequencingcosts

histology meets nextgen sequencing

pitch deck

arrayed oligos

TomoSeq

in situ sequencing

1

2

3

Principle: Capturing mRNA
on an arrayed microscope slide

Principle:
Mechanical sectioning
subsequent reconstruction

Principle:
Reverse transcription and amplification directly in tissue. 

Labeling methods

pitch deck

labeling of biomarkers in tissue

in situ hybdridization (ISH)

immmunohistochemistry (IHC)

fluorescent proteins (FP)

signal to noise ratio

• Target: RNA / DNA
• Probe: cDNA/cRNA

• Target: Endogenously expressed proteins
• Probe: antibodies

• Target: Transgenically expressed proteins
• Probe: viral vectors, transgenic animals.

business model

pitch deck

2-sided. B2B and B2C clients

x

client
prioritization

the team

pitch deck

daniel fürth

viktor ängmo

co-founder

professional experience

• Doctoral student
  - Department of Neuroscience,         Karolinska Institutet

Education

• Bachelor in Medical Science
  - Karolinska Institutet

co-founder
professional experience

• Business Development Manager
  - MTG technology

Education

• MSc in Entreprenuership & Business Creation Biotechnology
  - Chalmers University of Technology & Gothenburg University

CEO
professional experience

• Business analyst intern
  GU ventures

Education

• MSc in Entreprenuership
  & Business Creation Biotechnology
  - Chalmers University of Technology & Gothenburg University

malin kjällström

Histohub AB
Org. nr. 559093-0805

Stockholm

Ingemarsgatan 3a

113 54, Stockholm

the team

pitch deck

konstantinos meletis

armita golkar

scientific advisory board member

professional experience

• Associate Professor department of neuroscience
  - Karolinska Institutet

Education

• Ph.D. cell and molecular biology
  Karolinska Instituet
  Post doc. MIT

scientific advisory board member

professional experience

• Reseracher department of clinical neuroscience
  - Karolinska Institutet

Education

• Ph.D. psychology/neuroscience

scientific advisory board

vision

pitch deck

Building and managing cartographic maps of every organ in the body.

Spearheading technology for dealing with these data.

Babylonian city of Nippur (1400 BC)

Theatrum Orbis Terrarum (1570)
 

Google Maps (2005)
Noel Gordon, Jens Rasmussen (Where 2 Technologies)

vision

pitch deck

Building and managing cartographic maps of every organ in the body.

Spearheading technology for dealing with these data.

Je H. Lee

Assistant Professor

M.D., Ph.D.

Was first to ever develop
full transcriptome in situ
sequencing while at Harvard

cloud storage

intellectual asset portfolio

front end
user verification
account

cloud SSD backend

AWS S3 storage

1

2

3

• End user registers for an account at histoflurp.com Freemium model up to a certain limit (10 Gb).
   
• histo.io account is linked against our cloud backend which with SSD can quickly serve up images and content for use with our software suite.
   
• Permanent storage of images is done at
  amazon S3 AWS.

researcher
end user

contents

a.    Pitch Deck:   product, buisiness model, vision, team.

b.    Intellectual Asset Portfolio: what is unique about the product?

c.    Market: size, growth, beachhead, dynamics, competition.

d.    Monetization: B2C and B2B offers.

e.    Operation: costs, legal compliance, headcounts.

f.     Appendix: appendix

Next-Gen Sequencing for oncology biopsy is our beachhead market

market

• The primary industry of focus is the industry for Wholebrain is in the next gen sequencing market for Oncology.  
   
• Current therapy selection decisions are based on the outcome of a biopsy tests. Most common tests are immunoassays, sequencing or Histology to select a treatment.
   
• The ideal test can provide the pathologist with enough data to prescribe the correct therapy and not risk of prescribing a therapy without effect.
   
• The current state of data granularity on the sequencing methods is “single-cell – gene expression”. It can reveal rare cellular properties and biologically meaningful cell-to-cell variability. Still,  pathologists are blindfolded when it comes to understanding the cause of the cancer for a patient in subject. Resulting in risk of wrong therapy selection.  
   
• To be able to reach the ideal test, two pieces of data needs to be added to the biopsy test. 1) sub-cell building blocks (mRNA) and 2) spatial information. With this information you are able to find the driver of mutations and the pathways.
   
• The oncology sequencing market now embarks on a next phase, where numerous of companies all across the value chain will collectively work towards the goal of reaching this “Spatially-resolved Transcriptomics”.

Oncology Sequencing Market State

Sequencing is one method for choosing oncology therapy

Oncology
Health care chain

Predict

Diagnose

Inform

Treat

Risk assessment

Definitive diagnosis

Prognosis

Screening

Therapy selection

Development
resistance screening

Monitoring

Follow-up

Diagnosis

Histopathology

Immunoassays

Sequencing

NextGen Sequencing (NGS) market is estimated to grow at  20% CAGR and reach 12 billion USD in 2021

market

​Our main target group are Research Institutes buying, reagents in North America and Europe working on RNA based methods as they make up the vast majority of the market.

Total NGS Market 2016-2021 (BUSD)

Total NGS Market segmented (2015)

Market entering strategy

market

We can enter that market by grabbing a share of the Tertiary Software Market that is suffering from poor tools to provide insights on what reagents to buy

Annual budget for software to analyze NGS data

Average time spent analyzing NGS data

2

1

3

The market is fueled by massive investments in precision based medicine

market